Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Mévidette El Madani"'
Publikováno v:
Egyptian Journal of Anaesthesia, Vol 39, Iss 1, Pp 157-166 (2023)
ABSTRACTRecurrent ischemic stroke risk after transient ischemic attack was underestimated by most of epidemiological studies due to the widespread use of very different and sometimes restrictive definitions for recurrent stroke instead of a standard
Externí odkaz:
https://doaj.org/article/075d501f3c8c4fe5800f5aaa8b71df47
Autor:
Hend Abd-Allah, John Youshia, Gehad A. Abdel Jaleel, Azza Hassan, Mevidette El Madani, Maha Nasr
Publikováno v:
Pharmaceutics, Vol 16, Iss 1, p 153 (2024)
Oleuropein is the main constituent of olive leaf extract, and it has shown antioxidant and gastroprotective properties against gastric ulcers. Chitosan nanoparticles are known for their mucoadhesive abilities, and consequently, they can increase the
Externí odkaz:
https://doaj.org/article/8a8ceedcac644e8a9e4acbd30c1ebc42
Autor:
Suzan Boutary, Marie Caillaud, Mévidette El Madani, Jean-Michel Vallat, Julien Loisel-Duwattez, Alice Rouyer, Laurence Richard, Céline Gracia, Giorgia Urbinati, Didier Desmaële, Andoni Echaniz-Laguna, David Adams, Patrick Couvreur, Michael Schumacher, Charbel Massaad, Liliane Massaad-Massade
Publikováno v:
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Boutary et al. describe siRNA based therapy conjugated with squalene nanoparticles as an efficient approach to normalize PMP22 protein levels, restore locomotor activity, electrophysiological parameters and function of myelin sheath in CMT1A mouse mo
Externí odkaz:
https://doaj.org/article/1040014b286640ea9f55ad4f4445c8c9
Autor:
Jean-Michel Vallat, Didier Desmaële, Laurence Richard, Céline Gracia, Julien Loisel-Duwattez, Marie Caillaud, Mévidette El Madani, David Adams, Alice Rouyer, Liliane Massaad-Massade, Patrick Couvreur, Michael Schumacher, Giorgia Urbinati, Andoni Echaniz-Laguna, Suzan Boutary, Charbel Massaad
Publikováno v:
Communications Biology
Communications Biology, Nature Publishing Group, 2021, 4 (1), ⟨10.1038/s42003-021-01839-2⟩
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Communications Biology, 2021, 4 (1), pp.317. ⟨10.1038/s42003-021-01839-2⟩
Communications Biology, Nature Publishing Group, 2021, 4 (1), ⟨10.1038/s42003-021-01839-2⟩
Communications Biology, Vol 4, Iss 1, Pp 1-14 (2021)
Communications Biology, 2021, 4 (1), pp.317. ⟨10.1038/s42003-021-01839-2⟩
Charcot-Marie-Tooth disease type 1 A (CMT1A) lacks an effective treatment. We provide a therapy for CMT1A, based on siRNA conjugated to squalene nanoparticles (siRNA PMP22-SQ NPs). Their administration resulted in normalization of Pmp22 protein level
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00ba7e1ad7fba100a835e29b9666018f
https://hal.archives-ouvertes.fr/hal-03189470/document
https://hal.archives-ouvertes.fr/hal-03189470/document
Publikováno v:
Journal of Controlled Release
Journal of Controlled Release, Elsevier, 2020, 321, pp.616-628. ⟨10.1016/j.jconrel.2020.02.032⟩
Journal of Controlled Release, Elsevier, 2020, 321, pp.616-628. ⟨10.1016/j.jconrel.2020.02.032⟩
International audience; In 1998, the RNA interference discovery by Fire and Mello revolutionized the scientific and therapeutic world. They showed that small double-stranded RNAs, the siRNAs, were capable of selectively silencing the expression of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::711265ef13a8805e8d4d24dfca3fd8ae
https://pubmed.ncbi.nlm.nih.gov/32087301
https://pubmed.ncbi.nlm.nih.gov/32087301
Autor:
Jonathan Lopez, Mévidette El-Madani, Michel Tod, Julien Péron, Pauline Corbaux, Gilles Freyer, Benoit You, Denis Maillet
Publikováno v:
European Journal of Cancer
European Journal of Cancer, 2019, 120, pp.40-46. ⟨10.1016/j.ejca.2019.08.002⟩
European Journal of Cancer, Elsevier, 2019, 120, pp.40-46. ⟨10.1016/j.ejca.2019.08.002⟩
European Journal of Cancer, 2019, 120, pp.40-46. ⟨10.1016/j.ejca.2019.08.002⟩
European Journal of Cancer, Elsevier, 2019, 120, pp.40-46. ⟨10.1016/j.ejca.2019.08.002⟩
Background Determining the optimal biological dose (OBD) has been described as an alternative strategy to the maximum tolerated doses (MTDs) for identifying the recommended phase II trial doses (RP2Ds) of phase I anti-cancer therapies. However, the c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3a753543915274504fbaa0ea18214d8
https://pubmed.ncbi.nlm.nih.gov/31479946
https://pubmed.ncbi.nlm.nih.gov/31479946
Autor:
Gilles Freyer, Benoit You, Jérôme Guitton, Pierre-Jean Valette, Francoise Berger, Philippe A. Cassier, Thibaud Lefort, Mévidette El-Madani, Joël Lachuer, Catherine Barrois, K. Slimane, Michel Tod, Claire Rodriguez-Lafrasse, Emilie Henin
Publikováno v:
Future Oncology. 11:1511-1518
ABSTRACT Optimal development of targeted drug combinations is one of the future challenges to be addressed. Computerization and mathematical models able to describe biological phenomena and to simulate the effects of changes in experimental condition
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c296d1a0df8115a29df46b0cb0211369
https://doi.org/10.2217/fon.15.49
https://doi.org/10.2217/fon.15.49
Autor:
Claire Rodriguez-Lafrasse, Bassant M. M. Ibrahim, Siham M. El-Shenawy, Julien Péron, Benoit You, Gilles Freyer, Jérôme Guitton, Denis Maillet, Osama A. Badary, Marie-Claude Gagnieu, Olivier Colomban, Pierre-Jean Valette, Catherine Barrois, Thibaud Lefort, Ebtehal El-Demerdash, Michel Tod, Philippe A. Cassier, Mévidette El-Madani, Juliette Hommel-Fontaine
Publikováno v:
Future oncology (London, England). 13(8)
Aim: This novel multiparameter Phase I study aimed to optimize doses/dosing schedules of everolimus and sorafenib drug combination, based on modeling/simulation (NCT01932177). Patients & methods: About 26 patients with solid tumors were treated in fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3bf4c1767a7c5d0bcce1ef61c8becd6
https://pubmed.ncbi.nlm.nih.gov/28076966
https://pubmed.ncbi.nlm.nih.gov/28076966